Related references
Note: Only part of the references are listed.Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition
Michel M. Sun et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2020)
Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies
Carl W. Noble et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2020)
An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors
Aine O'Reilly et al.
SUPPORTIVE CARE IN CANCER (2020)
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Tawnie J. Braaten et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Hamzah Abu-Sbeih et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response
Melanie H. Smith et al.
ARTHRITIS CARE & RESEARCH (2019)
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman R. G. Stroud et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Myositis as an adverse event of immune checkpoint blockade for cancer therapy
Mohsin Shah et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette et al.
HORMONE AND METABOLIC RESEARCH (2019)
Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review
Evan T. Hall et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies Systematic review
Annette Johansen et al.
NEUROLOGY (2019)
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini et al.
ONCOLOGIST (2019)
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system
Pushkar Aggarwal
EXPERT OPINION ON DRUG SAFETY (2019)
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V. Ellen Maher et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment
Yoshihiko Sakata et al.
LUNG CANCER (2019)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors
Alberto Pavana et al.
ONCOLOGIST (2019)
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
Blake M. Warner et al.
ONCOLOGIST (2019)
The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders
Chanjuan Ma et al.
CANCER IMMUNOLOGY RESEARCH (2019)
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Daniel Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Douglas B. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis
Brandon T. Larsen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Lihu Gu et al.
BMC CANCER (2019)
Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis
H. K. Akturk et al.
DIABETIC MEDICINE (2019)
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
Audrey Simonaggio et al.
JAMA ONCOLOGY (2019)
Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
Michael S. Hughes et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune dysregulation in cancer patients developing immune-related adverse events
Shaheen Khan et al.
BRITISH JOURNAL OF CANCER (2019)
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y. Lim et al.
CLINICAL CANCER RESEARCH (2019)
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Alvaro Moreira et al.
EUROPEAN JOURNAL OF CANCER (2019)
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Omar Hasan Ali et al.
EUROPEAN JOURNAL OF CANCER (2019)
A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
Patrick Arnaud-Coffin et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs
Arianna Draghi et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Emily Coleman et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis
Laura C. Cappelli et al.
RHEUMATOLOGY (2019)
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer
Yukihiro Toi et al.
JAMA ONCOLOGY (2019)
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
Omar Mamlouk et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors
Rebecca Karp Leaf et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy
Karen Bitton et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature
Cassandra Calabrese et al.
RMD OPEN (2019)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review
Noha Abdel-Wahab et al.
ANNALS OF INTERNAL MEDICINE (2018)
Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area
Hassan Mir et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
Alexander T. Faje et al.
CANCER (2018)
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
Francois-Xavier Danlos et al.
EUROPEAN JOURNAL OF CANCER (2018)
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
Yinghong Wang et al.
INFLAMMATORY BOWEL DISEASES (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
Eleonora De Martin et al.
JOURNAL OF HEPATOLOGY (2018)
PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies
Teerin Liewluck et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis
B. L. Adler et al.
JOURNAL OF INTERNAL MEDICINE (2018)
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Jacob Siegel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
Michael F. Gowen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
Sara Valpione et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
Laura C. Cappelli et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C. Santini et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study
Pengfei Cui et al.
CANCER MEDICINE (2018)
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
Yinghong Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
Julie R. Brahmer et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
Shiro Kimbara et al.
CANCER SCIENCE (2018)
Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution
Celine Anquetil et al.
CIRCULATION (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Mehdi Touat et al.
NEUROLOGY (2018)
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Priyanka C. Iyer et al.
THYROID (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Predictors of immunotherapy-induced immune-related adverse events
A. Kartolo et al.
CURRENT ONCOLOGY (2018)
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis
Teppei Yamaguchi et al.
LUNG CANCER (2018)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang et al.
NATURE MEDICINE (2018)
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
Nicolas Delanoy et al.
Lancet Haematology (2018)
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Daniel H. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study
Marie Kostine et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
M. H. Pollack et al.
ANNALS OF ONCOLOGY (2018)
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
Tomoko Kobayashi et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2018)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
S. Cuzzubbo et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo
Maiana Larsabal et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
Laura C. Cappelli et al.
ARTHRITIS CARE & RESEARCH (2017)
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Florie Bertrand et al.
NATURE COMMUNICATIONS (2017)
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
Daniel Y. Wang et al.
ONCOIMMUNOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Renal complications of immune checkpoint blockade
Naoka Murakami et al.
CURRENT PROBLEMS IN CANCER (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput et al.
ANNALS OF ONCOLOGY (2017)
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Viktoria Bergqvist et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series
Patrizio Caturegli et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
Eduard Cornelis Verschuren et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
L. Marthey et al.
JOURNAL OF CROHNS & COLITIS (2016)
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Frank B. Cortazar et al.
KIDNEY INTERNATIONAL (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options
Saad A. Khan et al.
JAMA ONCOLOGY (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Hansje-Eva Teulings et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A. Tarhini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
Le Min et al.
CLINICAL CANCER RESEARCH (2015)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
C. Lebbe et al.
ANNALS OF ONCOLOGY (2014)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
Vafa Shahabi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
